VENLO, The Netherlands, May 4, 2015 /PRNewswire/ --
QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2014 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2014 has been filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2015, a copy of which can be found on the website of the SEC at http://www.sec.gov or in the 'Financial Information' section of the 'Investors' section of our website at http://www.qiagen.com/About-Us/Investors/ . QIAGEN will provide printed copies of the 2014 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2014 Annual Report please contact: IR@qiagen.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2014, QIAGEN employed approximately 4,300 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Investor Relations:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Email: ir@qiagen.com
